Specific behaviour ‐ threat or injury to self or others within 24 hours ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global outcome: no overall improvement ‐ at 30 minutes · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes global outcome: no overall improvement ‐ at 60 minutes compared with BENZODIAZEPINE: b. LORAZEPAM (very low certainty).
1 finding from 1 review
Adverse effects: specific ‐ dystonia · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects: specific ‐ dystonia (only reported if occurred in… compared with BENZODIAZEPINE: b. LORAZEPAM (very low certainty).
1 finding from 1 review
Specific behaviours ‐ agitation: average change score at 2 hours CABS · patients with psychosis‐induced aggression or agitation
1 finding from 1 review
Adverse effects: Specific ‐ hypertonia/rigidity (only reported if occurred in ≥9%) during 24 hours · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects: specific ‐ hypertonia/rigidity (only reported if… compared with BENZODIAZEPINE: b. LORAZEPAM (very low certainty).
1 finding from 1 review
Economic outcome ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tranquillisation or asleep ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Repeated need for rapid tranquillisation ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Specific behaviour ‐ threat or injury to self or others ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global outcome Need for rescue drug · patients with psychosis‐induced aggression or agitation
HALOPERIDOL showed no clear difference in global outcome Need for rescue drug compared with BENZODIAZEPINE: c. MIDAZOLAM (low certainty).
1 finding from 1 review
Adverse drug effects · patients with psychosis‐induced aggression or agitation
HALOPERIDOL showed no clear difference in adverse effects ‐ general ‐ one or more drug‐related adverse effect compared with BENZODIAZEPINE: c. MIDAZOLAM (low certainty).
1 finding from 1 review
Economic outcome ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Specific behaviour: aggression ‐ important decrease in aggression · people with long‐term aggression in psychosis
HALOPERIDOL leads to lower specific behaviour: aggression ‐ important decrease in aggression compared with OTHER ANTIPSYCHOTICS (high certainty).
1 finding from 1 review
no estimate extracted
83 participants
High
Repeated need for rapid tranquillisation · people with long‐term aggression in psychosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Specific behaviour ‐ threat or injury to self or others average change score (ABS, high = worse) at 2 hours · people with long‐term aggression in psychosis
HALOPERIDOL leads to lower specific behaviours ‐ threat or injury to others/self compared with OTHER ANTIPSYCHOTICS (high certainty).
1 finding from 1 review
no estimate extracted
83 participants
High
Adverse effects ‐ any serious, specific adverse effects · people with long‐term aggression in psychosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global outcomes ‐ overall improvement · people with long‐term aggression in psychosis
HALOPERIDOL leads to lower global outcomes ‐ overall improvement compared with OTHER ANTIPSYCHOTICS (high certainty).
1 finding from 1 review
no estimate extracted
83 participants
High
Leaving the study early · people with long‐term aggression in psychosis
HALOPERIDOL showed no clear difference in leaving the study early compared with OTHER ANTIPSYCHOTICS (low certainty).
1 finding from 1 review
Economic outcomes · people with long‐term aggression in psychosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinically important response to treatment (short term) · patients with schizophrenia
Haloperidol showed no clear difference in clinically important response to treatment (short term) compared with first‐generation antipsychotics (low certainty).
1 finding from 1 review